ARK Next Generation Internet ETF vs Becton Dickinson and Co — how do they compare? ARK Next Generation Internet ETF trades at $148.16, while Becton Dickinson and Co trades at $181.29 (market cap $49.41B). The key difference: Becton Dickinson and Co pays a 2.32% dividend while ARK Next Generation Internet ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | BDX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $185.39 |
52-Week Low | $114.45 | $138.62 |
Market Cap | — | $49.41B |
Enterprise Value | — | $65.51B |
Dividend Yield | — | 2.32% |
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $147.92, up 3.11% today, with bullish technical signals from moving averages and a neutral oscillator stance. The ETF focuses on next-generation internet companies including AI and cloud infrastructure plays. Recent analysis highlights near-term headwinds from elevated capital spending but maintains long-term growth potential in agentic AI and physical AI technologies.
The ETF faces market skepticism around current AI infrastructure investments but offers exposure to innovative technology leaders. Key risks include sector concentration and volatility, while institutional interest remains strong in transformative technology themes driving long-term growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →